Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kletting

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Medical Physics|June 16, 2018
Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at riskLuis David Jiménez-Franco, Peter Kletting, Ambros J Beer, et al.
Medical Physics|September 3, 2016
Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noiseDeni Hardiansyah, Wei Guo, Peter Kletting, et al.
Medical Physics|October 7, 2019
Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in <sup>177</sup> Lu-PSMA therapyAndreas Rinscheid, Peter Kletting, Matthias Eiber, et al.
Zeitschrift Fur Medizinische Physik|January 7, 2019
A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapyAndreas Rinscheid, Jeesoo Lee, Peter Kletting, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 13, 2016
Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide TherapyDeni Hardiansyah, Nusrat Jihan Begum, Peter Kletting, et al.
Nuklearmedizin. Nuclear Medicine|November 2, 2020
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligandsNusrat Jihan Begum, Gerhard Glatting, Matthias Eiber, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|July 26, 2017
Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic modelDeni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, et al.
Medical Physics|July 23, 2011
Optimal preloading in radioimmunotherapy with anti-cD45 antibodyPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2021
A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in RatsNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 15, 2015
Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody RadioimmunotherapyChristian Maaß, Peter Kletting, Donald Bunjes, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Medical Physics|June 16, 2018
Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at riskLuis David Jiménez-Franco, Peter Kletting, Ambros J Beer, et al.
Medical Physics|September 3, 2016
Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noiseDeni Hardiansyah, Wei Guo, Peter Kletting, et al.
Medical Physics|October 7, 2019
Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in <sup>177</sup> Lu-PSMA therapyAndreas Rinscheid, Peter Kletting, Matthias Eiber, et al.
Zeitschrift Fur Medizinische Physik|January 7, 2019
A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapyAndreas Rinscheid, Jeesoo Lee, Peter Kletting, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 13, 2016
Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide TherapyDeni Hardiansyah, Nusrat Jihan Begum, Peter Kletting, et al.
Nuklearmedizin. Nuclear Medicine|November 2, 2020
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligandsNusrat Jihan Begum, Gerhard Glatting, Matthias Eiber, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|July 26, 2017
Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic modelDeni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, et al.
Medical Physics|July 23, 2011
Optimal preloading in radioimmunotherapy with anti-cD45 antibodyPeter Kletting, Thomas Kull, Donald Bunjes, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2021
A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in RatsNouran R R Zaid, Peter Kletting, Gordon Winter, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 15, 2015
Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody RadioimmunotherapyChristian Maaß, Peter Kletting, Donald Bunjes, et al.
Pageof 5